» Articles » PMID: 35922643

Metabolomic and Proteomic Profiling in Bipolar Disorder Patients Revealed Potential Molecular Signatures Related to Hemostasis

Overview
Journal Metabolomics
Publisher Springer
Specialty Endocrinology
Date 2022 Aug 3
PMID 35922643
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Bipolar disorder (BD) is a mood disorder characterized by the occurrence of depressive episodes alternating with episodes of elevated mood (known as mania). There is also an increased risk of other medical comorbidities.

Objectives: This work uses a systems biology approach to compare BD treated patients with healthy controls (HCs), integrating proteomics and metabolomics data using partial correlation analysis in order to observe the interactions between altered proteins and metabolites, as well as proposing a potential metabolic signature panel for the disease.

Methods: Data integration between proteomics and metabolomics was performed using GC-MS data and label-free proteomics from the same individuals (N = 13; 5 BD, 8 HC) using generalized canonical correlation analysis and partial correlation analysis, and then building a correlation network between metabolites and proteins. Ridge-logistic regression models were developed to stratify between BD and HC groups using an extended metabolomics dataset (N = 28; 14 BD, 14 HC), applying a recursive feature elimination for the optimal selection of the metabolites.

Results: Network analysis demonstrated links between proteins and metabolites, pointing to possible alterations in hemostasis of BD patients. Ridge-logistic regression model indicated a molecular signature comprising 9 metabolites, with an area under the receiver operating characteristic curve (AUROC) of 0.833 (95% CI 0.817-0.914).

Conclusion: From our results, we conclude that several metabolic processes are related to BD, which can be considered as a multi-system disorder. We also demonstrate the feasibility of partial correlation analysis for integration of proteomics and metabolomics data in a case-control study setting.

Citing Articles

Lipid Biomarker Research in Bipolar Disorder: A Scoping Review of Trends, Challenges, and Future Directions.

Hiller J, Jangmo A, Tesli M, Jaholkowski P, Hoseth E, Steen N Biol Psychiatry Glob Open Sci. 2023; 3(4):594-604.

PMID: 37881590 PMC: 10593953. DOI: 10.1016/j.bpsgos.2023.07.004.


Application of Lipidomics in Psychiatry: Plasma-Based Potential Biomarkers in Schizophrenia and Bipolar Disorder.

Costa A, Rica L, Van De Bilt M, Zandonadi F, Gattaz W, Talib L Metabolites. 2023; 13(5).

PMID: 37233641 PMC: 10222421. DOI: 10.3390/metabo13050600.

References
1.
Al Awam K, Haussleiter I, Dudley E, Donev R, Brune M, Juckel G . Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. J Neural Transm (Vienna). 2014; 122 Suppl 1:S111-22. DOI: 10.1007/s00702-014-1224-0. View

2.
Bassot A, Prip-Buus C, Alves A, Berdeaux O, Perrier J, Lenoir V . Loss and gain of function of Grp75 or mitofusin 2 distinctly alter cholesterol metabolism, but all promote triglyceride accumulation in hepatocytes. Biochim Biophys Acta Mol Cell Biol Lipids. 2021; 1866(12):159030. DOI: 10.1016/j.bbalip.2021.159030. View

3.
Del Boccio P, Rossi C, Di Ioia M, Cicalini I, Sacchetta P, Pieragostino D . Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine. Proteomics Clin Appl. 2016; 10(4):470-84. DOI: 10.1002/prca.201500083. View

4.
Bulbul F, Eryigit A, Erbagci A, Selek S, Savas H . Alterations of Lipid-Lipoprotein and Leptin in Bipolar Disorder Associated with Clinic Process. Noro Psikiyatr Ars. 2017; 51(1):52-56. PMC: 5370263. DOI: 10.4274/npa.y6668. View

5.
Calderon-Guzman D, Hernandez-Islas J, Espitia Vazquez I, Barragan-Mejia G, Hernandez-Garcia E, Santamaria Del Angel D . Effect of toluene and cresols on Na+,K+-ATPase, and serotonin in rat brain. Regul Toxicol Pharmacol. 2005; 41(1):1-5. DOI: 10.1016/j.yrtph.2004.09.005. View